Curtiss F R
Am J Hosp Pharm. 1982 Nov;39(11):1975-7.
Recently enacted federal and state legislation reflect a gradual transition from cost-based reimbursement to rate-based reimbursement for hospital services; the implications of this trend for hospital pharmacists are discussed. Under "The Tax Equity and Fiscal Responsibility Act of 1982," Medicare hospital reimbursement is limited based on total hospital costs, effective for the 1983 fiscal reporting period. In addition, a target limit of costs for each hospital will be computed and hospitals will have positive and negative incentives to keep costs below this amount. These reimbursement changes calculate limits on the basis of costs per case, not costs incurred. These changes increasingly require hospitals to share in the risk of expenditures attributed to use of services. For hospital pharmacists, this means that the focus is changing from maximizing revenue from drug products to controlling unnecessary use and reducing departmental expense. Clinical pharmacy services will survive only if they are shown to be cost effective. Hospital pharmacists cannot afford to ignore the changing patterns of reimbursement; the consequences of unpreparedness and inaction may be decreased budgets and the relegation of hospital pharmacy practice to assembly-line economics.
最近颁布的联邦和州立法反映了医院服务从基于成本的报销向基于费率的报销的逐渐转变;讨论了这一趋势对医院药剂师的影响。根据“1982年税收公平与财政责任法案”,医疗保险医院报销基于医院总成本受到限制,从1983财年报告期开始生效。此外,将计算每家医院的成本目标限额,医院将有正向和负向激励措施来将成本控制在该金额以下。这些报销变化是根据每个病例的成本而非发生的成本来计算限额。这些变化越来越要求医院分担因服务使用而产生的支出风险。对于医院药剂师来说,这意味着重点正从使药品收入最大化转向控制不必要的使用并减少部门开支。临床药学服务只有在被证明具有成本效益时才能存续。医院药剂师不能忽视报销模式的变化;毫无准备和无所作为的后果可能是预算减少以及医院药学实践沦为流水线式的经济模式。